Ownership and insider activity for Calidi Biotherapeutics, Inc. (CLDI): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents.
Price
| Price | $1.17 |
| Market Cap | $1M |
| Exchange | AMEX |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-17 | Peoples George | A-Award | 4,000 | $5K |
| 2026-08-17 | Leftwich Scott | A-Award | 4,000 | $5K |
| 2026-08-17 | Stewart Alan R. | A-Award | 4,000 | $5K |
| 2026-08-17 | Jackson Andrew C. | A-Award | 14,000 | $19K |
| 2026-08-17 | Schoeneck James A | A-Award | 5,000 | $7K |
| 2026-08-17 | Poma Eric E | A-Award | 32,000 | $44K |
| 2026-08-17 | Fernandez Santidrian Antonio | A-Award | 16,000 | $22K |
| 2026-08-17 | Sanders Corazon (Corsee) D. | A-Award | 6,000 | $8K |
| 2026-06-17 | Sanders Corazon (Corsee) D. | |||
| 2025-12-12 | Camaisa Allan | S-Sale | 850 | $1K |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $420000 | $2.1M | $372000 | $2.0M | $9.6M | $5.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | $1.4M | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $513000 | $2.7M | $786000 | $4.3M | $10.2M | $6.3M |
| Property, Plant & Equipment | $723000 | $585000 | $1.1M | $5.3M | $2.9M | $1.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $1.9M | $3.4M | $2.6M | $10.0M | $14.2M | $8.9M |
| Accounts Payable | $822000 | $624000 | $2.1M | $2.9M | $2.1M | $595000 |
| Short-term Debt | $4.9M | $5.0M | $5.4M | $807000 | $3.2M | 0 |
| Total Current Liabilities | $8.9M | $26.0M | $43.0M | $10.2M | $9.5M | $3.9M |
| Long-term Debt | $6.4M | 0 | 0 | $2.1M | $600000 | $600000 |
| Total Liabilities | $24.3M | $26.0M | $53.0M | $18.3M | $12.2M | $5.1M |
| Retained Earnings | -$34.4M | -$44.9M | -$70.4M | -$99.6M | -$121.7M | -$141.6M |
| Total Equity | -$22.5M | -$22.6M | -$50.4M | -$8.2M | $1.5M | $3.8M |
| Total Debt | $11.7M | $5.2M | $6.0M | $7.2M | $7.0M | $2.6M |
| Net Debt | $11.3M | $3.0M | $5.6M | $5.2M | -$2.6M | -$3.0M |
| Working Capital | -$8.4M | -$23.2M | -$42.2M | -$5.9M | $731000 | $2.3M |
Financial Health
| Debt / Equity | 0.62 |
| Current Ratio | 1.68 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -29.02 |
Profitability
| Return on Equity | -372.86% |
| Return on Invested Capital | -347.09% |
| Return on Assets | -242.55% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CANF · CMND · CNSP · KZIA · QLGN · SILO · SNGX
Explore sector: Healthcare · Biotechnology
More sections of CLDI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks